Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Rhythm Pharmaceuticals, Inc. (RYTM) had Stock-Based Compensation of $28.74M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$48.50M |
|
$-47.98M |
|
$5.54M |
|
$42.96M |
|
$93.80M |
|
$-45.30M |
|
$-1.00M |
|
$-46.30M |
|
$-46.30M |
|
$-46.63M |
|
$-46.63M |
|
$-46.63M |
|
$-46.63M |
|
$-45.30M |
|
$-44.92M |
|
63.68M |
|
63.68M |
|
$-0.75 |
|
$-0.75 |
|
| Balance Sheet Financials | |
$360.68M |
|
$0.30M |
|
$12.05M |
|
$372.73M |
|
$129.46M |
|
-- |
|
$109.69M |
|
$239.15M |
|
$-11.91M |
|
$127.84M |
|
$133.58M |
|
63.91M |
|
| Cash Flow Statement Financials | |
$-63.66M |
|
$78.85M |
|
$31.61M |
|
$89.60M |
|
$136.11M |
|
$46.51M |
|
|
Stock-Based Compensation |
$28.74M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.79 |
|
-- |
|
-- |
|
-- |
|
-- |
|
88.57% |
|
-93.39% |
|
-93.39% |
|
-- |
|
-95.45% |
|
-98.93% |
|
$-63.66M |
|
-- |
|
-- |
|
-- |
|
0.13 |
|
0.29 |
|
1.86 |
|
48.47 |
|
391.60% |
|
-36.48% |
|
-12.51% |
|
-34.91% |
|
$2.09 |
|
$-1.00 |
|
$-1.00 |
|